Shizuoka Cancer Center Hospital, Shizuoka, Japan
Lung cancer survival was similar after carboplatin/gemcitabine versus vinorelbine/gemcitabine
Published in Pharma Investments, Ventures and Law Weekly, October 1st, 2006
According to a study from Japan, "Combined GC and combined GV are active and well tolerated chemotherapeutic regimens for patients with advanced NSCLC. The authors conducted a randomized Phase II study of GC versus GV to compare them in terms of efficacy and toxicity."
"One hundred twenty-eight patients with Stage IIIB or IV NSCLC were randomized to receive either carboplatin at an area under the curve of 5 on Day 1 combined with gemcitabine 1000 mg/m2 on Days 1 and 8...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- AGA Medical
AGA Medical files suit in Germany alleging patent infringement - Ablynx
Ablynx completes EUR 40 million series C financing - Advanced Biotherapy
Advanced Biotherapy enters into share purchase and debt restructure agreement - Affymetrix
Affymetrix files restated financial statements - Amylin Pharmaceuticals
Amylin converts all outstanding 2.25% convertible senior notes due 2008 - Bradley Pharmaceuticals
Bradley Pharmaceuticals announces initiatives to enhance shareholder value - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
